Well Health Labs, LLC

Well Health Labs, LLC was paid $954K by Medicaid between Nov 2020 and Dec 2024, across 35 billing codes. Its largest line is U0004, 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r — 31% of everything it billed.

Compared with peers

Next to other Clinical Medical Laboratory providers in Texas

Rank by total paid#70 of 436

Median peer was paid$17K

This provider vs. median55×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2020	166	$2K
2021	10,266	$194K
2022	13,201	$256K
2023	20,472	$291K
2024incomplete	16,601	$212K

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
U0004	2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r	31%	6,465	5,601	$299K
87798	Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism	24%	9,309	4,276	$232K
U0005	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2	10%	6,285	5,469	$98K
87631		8.9%	3,546	3,120	$85K
87635	Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe	5.5%	1,873	1,680	$53K
87150		5.0%	2,390	2,047	$48K
87481		2.7%	1,842	1,615	$26K
87651	Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe	1.8%	4,337	3,675	$17K
87500		1.2%	3,027	2,591	$12K
87486		1.1%	3,131	2,699	$11K
87581		1.1%	3,129	2,698	$11K
87541		1.1%	2,917	2,515	$11K

23 more codes

87633	Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets	<1%	393	$8K
87653		<1%	1,841	$6K
87640		<1%	1,841	$6K
87529		<1%	965	$5K
87641		<1%	1,661	$5K
87491	Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe	<1%	964	$4K
87591	Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe	<1%	963	$4K
87496		<1%	751	$3K
87563		<1%	691	$3K
87661	Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe	<1%	441	$2K
80307	Drug test(s), presumptive, any number of drug classes; immunoassay	<1%	207	$1K
87511		<1%	363	$1K
87551		<1%	122	$929.68
G0482	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed	<1%	46	$880.96
G0483	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed	<1%	64	$860.92
87086	Culture, bacterial; quantitative colony count, urine	<1%	421	$823.96
87801	Infectious agent detection by nucleic acid; amplified probe, multiple organisms	<1%	31	$176.91
81001		<1%	426	$143.54
80050	General health panel	<1%	13	$124.00
87498		<1%	212	$89.33
80061	Lipid panel	<1%	13	$31.06
83036	Hemoglobin; glycosylated (A1C)	<1%	12	$16.96
81003		<1%	14	$4.83

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialSHOAIB, MOHAMMAD (OWNER)